George A. Sprecace M.D., J.D., F.A.C.P. and Allergy Associates of New London, P.C.
www.asthma-drsprecace.com


Xolair (omilazubab) and Bronchial Asthma

Bronchial asthma continues to be the most under-treated serious disease in this country today, probably assuming that role from high blood pressure...the long-time leader in that dubious category of health care.  At least 10% of the American population has asthma.  The costs of the disease and its treatment exceed $20 billion yearly.  And over 5000 sufferers die annually, mostly unnecessarily, from this highly treatable disease.

The latest treatment approved for the treatment of asthma is a "humanized anti-IgE antibody" available by injection to neutralize the IgE antibody which in most cases is the allergic basis of the process.  So far its utility is restricted...if at all...the moderately severe and severe cases in children (age 12 and beyond) and adults.  But there are "issues" yet to be resolved:

Specialists like myself are trying to add this new modality, where indicated, to our treatment approaches for bronchial asthma. But the above issues must be addressed by the producing pharmaceutical company and its surrogates if its total potential - whatever that is - is to be achieved.  Not the least of these issues is the need to have the producer provide the product, pre-paid, to the physician for use in his patient - the producer thereafter seeking reimbursment from the managed care company.

GS


Return to:
Home
Categories
 
 

Copyright Notice (c) Copyright 1999-2024 Allergy Associates of New London, PC